AddLife Q3 2026 slides: profit surges 61% on margin gains, M&A ramps up

AddLife released its Q3 2026 interim report on October 21, 2026, revealing a 61% surge in profit before tax alongside expanding margins and brisk acquisition activity. The Swedish life science firm's shares dropped 1.3% to $183 after the announcement. The stock presently hovers near $185.3, midway between its 52-week trading range of $133 and $207.6, and has gained 19% year-to-date.

The presentation showcased robust growth across both segments, with Eastern Europe performing well and the UK market showing improvement. Ongoing labor disputes in Spain, however, posed regional challenges.

For Q3 2026, AddLife's net sales stood at SEK 2,599 million, marking a 7% year-over-year increase. This growth was a blend of 4% organic expansion and 3% acquisitions, partially offset by a 1% negative currency impact plus the sale of its UK endoscopy business in December 2025. Key performance indicators showed notable gains: Adjusted EBITA rose 11% to SEK 298 million, boosting EBITA margin to 11.5% from 11.1% previously.

Revenue growth came from SEK 102 million in organic gains and SEK 71 million from acquisitions, with currency translation adding SEK 24 million. Profit before tax rose to SEK 179 million, up 61% from SEK 111 million in Q3 2025, driven by volume growth, gross margin improvement, and revaluation of contingent consideration. CEO Fredrik Karlsson emphasized the company's strategy of steering clear of commoditized products and focusing on advanced offerings.

CFO Christina Kassman highlighted a one percentage point rise in gross margin, attributed to pricing adjustments and a greater proportion of advanced products in sales. Operating cash flow surged 62% to SEK 236 million from SEK 145 million, driven by improved working capital management. Net debt increased slightly to SEK 4,746 million, mainly due to a SEK 91 million foreign exchange translation effect, with debt-to-EBITDA still below the company's target of 3.0x.